However, high-dose therapy has been associated with an increased risk of causing haemolysis in G6PD-deficient patients, methaemoglobinaemia, gastrointestinal (GI) discomfort, etc. This is particularly challenging as the geographic distribution of G6PD deficiency, the most common inherited human enzymopathy [9], mirrors that of malaria because it provides some protection against the disease [9,10]. Here, G6PD is linked to malaria.